Characterization of the inhibition of hepatitis C virus entry by In vitro-generated and patient-derived oxidized low-density lipoprotein

Hepatology

Volumn 57, Issue 5, 2013, Pages 1716-1724

  Westhaus, Sandra ^a   Bankwitz, Dorothea ^b   Ernst, Stefanie ^a   Rohrmann, Katrin ^a   Wappler, Ilka ^b   Agné, Clemens ^a   Luchtefeld, Maren ^a   Schieffer, Bernhard ^a   Sarrazin, Christoph ^c   Manns, Michael P ^a   Pietschmann, Thomas ^b   Ciesek, Sandra ^a,b   Von Hahn, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ARTICLE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RNA REPLICATION; VIRUS ENTRY; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS VIRULENCE;

ANTIGENS, CD36; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELLS, CULTURED; DNA, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIPOPROTEINS, LDL; LIVER NEOPLASMS; VIRAL LOAD; VIRION; VIRUS REPLICATION;

EID: 84876700191     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26190     Document Type: Article

References (40)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115.
2. Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat 2012; 19: 1-8.
3. Alvisi G, Madan V, Bartenschlager R. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol 2011; 8: 258-269.
4. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. HEPATOLOGY 2012; 55: 998-1007.
5. Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. HEPATOLOGY 2007; 46: 1722-1731.
6. Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18: 281-285.
7. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941.
8. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805.
9. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886.
10. Rigotti A, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003; 24: 357-387.
11. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518-520.
12. Acton SL, Scherer PE, Lodish HF, Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 1994; 269: 21003-21009.
13. Rohrl C, Fruhwurth S, Schreier SM, Lohninger A, Dolischka A, Huttinger M, et al. Scavenger receptor, Class B, Type I provides an alternative means for beta-VLDL uptake independent of the LDL receptor in tissue culture. Biochim Biophys Acta 2010; 1801: 198-204.
14. Van Eck M, Hoekstra M, Out R, Bos IS, Kruijt JK, Hildebrand RB, Van Berkel TJ. Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J Lipid Res 2008; 49: 136-146.
15. Gu X, Lawrence R, Krieger M. Dissociation of the high density lipoprotein and low density lipoprotein binding activities of murine scavenger receptor class B type I (mSR-BI) using retrovirus library-based activity dissection. J Biol Chem 2000; 275: 9120-9130.
16. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025.
17. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007; 81: 8063-8071.
18. Grove J, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, et al. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol 2007; 81: 3162-3169.
19. Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Slowikowski MP, et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012; 57: 17-23.
20. Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54: 48-55.
21. Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, et al. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem 2012; 287: 31242-31257.
22. Zahid MN, Turek M, Xiao F, Thi VL, Guerin M, Fofana I, et al. The post-binding activity of scavenger receptor BI mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology 2012 18 Oct. doi:10.1002/hep.26097.
23. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006; 281: 18285-18295.
24. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. HEPATOLOGY 2006; 43: 932-942.
25. Jiang X, Yang Z, Chandrakala AN, Pressley D, Parthasarathy S. Oxidized low density lipoproteins-do we know enough about them? Cardiovasc Drugs Ther 2011; 25: 367-377.
26. Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol 2010; 610: 403-417.
27. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979; 76: 333-337.
28. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.
29. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 67-75.
30. Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. HEPATOLOGY 2011; 54: 1947-1955.
31. Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010; 138: 1875-1884.
32. Ciesek S, Westhaus S, Wicht M, Wappler I, Henschen S, Sarrazin C, et al. Impact of occludin intra- and inter-species variation on its co-receptor function for authentic hepatitis C virus particles. J Virol 2011; 85: 7613-7621.
33. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. HEPATOLOGY 2009; 49: 364-377.
34. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010; 84: 34-43.
35. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010; 84: 5751-5763.
36. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008; 82: 12020-12029.
37. Puente Navazo MD, Daviet L, Ninio E, McGregor JL. Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL). Arterioscler Thromb Vasc Biol 1996; 16: 1033-1039.
38. Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 2010; 13: 39-75.
39. Nakhjavani M, Mashayekh A, Khalilzadeh O, Asgarani F, Morteza A, Omidi M, Froutan H. Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 111-116.
40. Pfutzner A, Efstrathios K, Lobig M, Armbruster FP, Hanefeld M, Forst T. Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays-an evaluation with samples from the PIOstat study. Clin Lab 2009; 55: 275-281.